Registered title, quoted from ClinicalTrials.gov
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
An open trial on glioma, registered on ClinicalTrials.gov. Led by Beijing Tiantan Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05577091, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Patients with history of glioblastoma are diagnosed with recurrent glioblastoma and residual tumor after intracranial tumor resection/biopsy performed in Beijing Tiantan Hospital.
Inclusion criterion 2
Patients who finished radiotherapy or temozolomide/bevacizumab or other drugs for at least 4 weeks. All toxicities of prior treatment should be defined as less than or equal to grade 1 (except for toxicities such as hair loss or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 5.0).
Inclusion criterion 3
Kanovsky Performance Status (KPS) ≥ 70.
Inclusion criterion 6
Kanovsky Performance Status (KPS) ≤ 70.
Exclusion criterion 1
White blood cells (WBC) > 3.50×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 8
Platelet ≥ 200×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 9
Hemoglobin ≥ 120 g/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 10
Total bilirubin ≤ 20 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 11
Aspartic acid aminotransferase (AST) ≤ 2.5×42 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 12
Alanine aminotransferase (ALT) ≤ 2.5×41 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 13
Serum creatinine ≤ 90 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 14
Fertile women: a negative serum pregnancy test (performed within 14 days prior to PBMC collection unless otherwise noted).
Inclusion criterion 17
The patient agrees that contraception should be used in patients of childbearing age for at least 3 months from screening to the last infusion of Tris-CAR-T cells. The period of childbearing age is defined as unsurgically neutered (men and women) or without menopause for more than 1 year (women only).
Inclusion criterion 18
Special cases: pregnancy or lactation.
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05577091, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age: 18 years to 70 years (including cut-off values).
- Patients with history of glioblastoma are diagnosed with recurrent glioblastoma and residual tumor after intracranial tumor resection/biopsy performed in Beijing Tiantan Hospital.
- Patients who finished radiotherapy or temozolomide/bevacizumab or other drugs for at least 4 weeks. All toxicities of prior treatment should be defined as less than or equal to grade 1 (except for toxicities such as hair loss or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 5.0).
- Patients who is suitable for craniotocerebrospinal fluid shunt and attachment (Ommaya device) implantation confirmed by a competent physician.
- Patients and/or legal representative is able to sign written informed consent.
- Kanovsky Performance Status (KPS) ≥ 70.
- According to the researchers' judgment, the life expectancy ≥ 8 weeks.
- White blood cells (WBC) > 3.50×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Platelet ≥ 200×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Hemoglobin ≥ 120 g/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Total bilirubin ≤ 20 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Aspartic acid aminotransferase (AST) ≤ 2.5×42 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Alanine aminotransferase (ALT) ≤ 2.5×41 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Serum creatinine ≤ 90 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
- Blood oxygen saturation ≥ 95% (performed within 14 days prior to PBMC collection unless otherwise noted).
- Seronegative of the combination of human immunodeficiency virus (HIV) antibody (Ab) (performed within 14 days prior to PBMC collection unless otherwise noted).
- Fertile women: a negative serum pregnancy test (performed within 14 days prior to PBMC collection unless otherwise noted).
- The patient agrees that contraception should be used in patients of childbearing age for at least 3 months from screening to the last infusion of Tris-CAR-T cells. The period of childbearing age is defined as unsurgically neutered (men and women) or without menopause for more than 1 year (women only).
Exclusion Criteria:
- Kanovsky Performance Status (KPS) ≤ 70.
- Highly allergic constitution or severe allergies history.
- Those who have psychiatric or psychological diseases and cannot cooperate with treatment and efficacy assessment.
- Receive other drug trials within 60 days before enrollment, or receive other routine treatment in non-experimental designs for glioblastoma, such as stereotactic radiation therapy or placement of carmustine wafers.
- Combined with infection, active infection, fever of unknown cause.
- Combined with serious or unstable heart, lung, liver, kidney and hematopoietic system diseases, including active hepatitis.
- Combined with inflammation and immune system diseases (such as rheumatoid arthritis), or known immunosuppressive diseases.
- Combined with neurological diseases, such as diffuse leptomeningeal disease, or neurodegenerative diseases.
- Known allergies to immunotherapy and related cellular products.
- Patients who have received any gene therapy before.
- Long-term use of immunosuppressants is required for any reason.
- Patients with a history of organ transplantation or who are waiting for organ transplantation.
- Special cases: pregnancy or lactation.
- Other circumstances in which the investigators believe the patient is unsuitable for this trial.
Quoted from ClinicalTrials.gov, NCT05577091, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05577091, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.